Engin Ayse Basak, Karahalil Bensu, Karakaya Ali Esat, Engin Atilla
Ayse Basak Engin, Bensu Karahalil, Ali Esat Karakaya, Department of Toxicology, Faculty of Pharmacy, Gazi University, TR 06330 Hipodrom, Ankara, Turkey.
World J Gastroenterol. 2015 Mar 28;21(12):3636-43. doi: 10.3748/wjg.v21.i12.3636.
To evaluate how Helicobacter pylori (H. pylori) is able to evade the immune response and whether it enhances systemic immune tolerance against colorectal cancer.
This prospective randomized study involved 97 consecutive colorectal cancer patients and 108 cancer-free patients with extra-digestive diseases. Colorectal cancer and cancer-free patients were assigned into subgroups according to H. pylori IgG seropositivity. Exposure to H. pylori was determined by IgG seropositivity which was detected by enzyme linked immunoassay (ELISA). Serum neopterin levels were measured by ELISA. Serum tryptophan, kynurenine, and urinary biopterin concentrations were measured by high performance liquid chromatography. Serum nitrite levels were detected spectrophotometrically. Serum indoleamine 2,3-dioxygenase activity was estimated by the kynurenine to tryptophan ratio and by assessing the correlation between serum neopterin concentrations and the kynurenine to tryptophan ratio. The frequencies of increased serum kynurenine to tryptophan ratio of H. pylori seronegative and seropositive colorectal cancer subgroups were estimated by comparing them with the average kynurenine to tryptophan ratio of H. pylori seronegative tumor-free patients.
Compared with respective controls, in both H. pylori seronegative and seropositive colorectal cancer patients, while serum tryptophan levels were decreased (controls vs patients; seronegative: 20.37 ± 0.89 μmol/L vs 15.71 ± 1.16 μmol/L, P < 0.05; seropositive: 20.71 ± 0.81 μmol/L vs 14.97 ± 0.79 μmol/L, P < 0.01) the kynurenine to tryptophan ratio was significantly increased (controls vs patients; seronegative: 52.85 ± 11.85 μmol/mmol vs 78.91 ± 8.68 μmol/mmol, P < 0.01, seropositive: 47.31 ± 5.93 μmol/mmol vs 109.65 ± 11.50 μmol/mmol, P < 0.01). Neopterin concentrations in cancer patients were significantly elevated compared with controls (P < 0.05). There was a significant correlation between serum neopterin levels and kynurenine/tryptophan in control and colorectal cancer patients groups (rs = 0.494, P = 0.0001 and rs = 0.293, P = 0.004, respectively). Serum nitrite levels of H. pylori seropositive cancer cases were significantly decreased compared with seropositive controls (controls vs patients; 26.04 ± 2.39 μmol/L vs 20.41 ± 1.48 μmol/L, P < 0.05) The decrease in the nitrite levels of H. pylori seropositive cancer patients may be attributed to excessive formation of peroxynitrite and other reactive nitrogen species.
A significantly high kynurenine/tryptophan suggested that H. pylori may support the immune tolerance leading to cancer development, even without an apparent upper gastrointestinal tract disease.
评估幽门螺杆菌(H. pylori)如何逃避免疫反应,以及它是否增强对结直肠癌的全身免疫耐受。
这项前瞻性随机研究纳入了97例连续的结直肠癌患者和108例患有消化外疾病的无癌患者。根据H. pylori IgG血清阳性将结直肠癌患者和无癌患者分为亚组。通过酶联免疫吸附测定(ELISA)检测的IgG血清阳性来确定是否感染H. pylori。通过ELISA测量血清新蝶呤水平。通过高效液相色谱法测量血清色氨酸、犬尿氨酸和尿生物蝶呤浓度。用分光光度法检测血清亚硝酸盐水平。通过犬尿氨酸与色氨酸的比率以及评估血清新蝶呤浓度与犬尿氨酸与色氨酸比率之间的相关性来估计血清吲哚胺2,3-双加氧酶活性。通过将H. pylori血清阴性和血清阳性结直肠癌亚组的血清犬尿氨酸与色氨酸比率的增加频率与H. pylori血清阴性无肿瘤患者的平均犬尿氨酸与色氨酸比率进行比较来估计。
与各自的对照组相比,在H. pylori血清阴性和血清阳性的结直肠癌患者中,虽然血清色氨酸水平降低(对照组与患者组;血清阴性:20.37±0.89μmol/L对15.71±1.16μmol/L,P<0.05;血清阳性:20.71±0.81μmol/L对14.97±0.79μmol/L,P<0.01),但犬尿氨酸与色氨酸的比率显著增加(对照组与患者组;血清阴性:52.85±11.85μmol/mmol对78.91±8.68μmol/mmol,P<0.01,血清阳性:47.31±5.93μmol/mmol对109.65±11.50μmol/mmol,P<0.01)。癌症患者的新蝶呤浓度与对照组相比显著升高(P<0.05)。在对照组和结直肠癌患者组中,血清新蝶呤水平与犬尿氨酸/色氨酸之间存在显著相关性(rs = 0.494,P = 0.0001和rs = 0.293,P = 0.004)。与血清阳性对照组相比,H. pylori血清阳性癌症病例的血清亚硝酸盐水平显著降低(对照组与患者组;26.04±2.39μmol/L对20.41±1.48μmol/L,P<0.05)H. pylori血清阳性癌症患者亚硝酸盐水平的降低可能归因于过氧亚硝酸盐和其他活性氮物质的过度形成。
显著升高的犬尿氨酸/色氨酸表明,即使没有明显的上消化道疾病,H. pylori也可能支持导致癌症发展的免疫耐受。